Bioretec
2.83 EUR -2.41%1,357 investors are following this company
Bioretec is a medical technology company. The company specializes in the development of medical devices. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other material for bone and soft tissue injuries. In addition to the main business, service and associated ancillary services are also offered. Bioretec operates worldwide with the largest presence in the Nordic region.
P/E (24e)
-15.06
EV/EBIT (adj.) (24e)
-15.78
P/B (24e)
12.13
Dividend yield-% (24e)
-
Target price
3.00 EUR
Recommendation
Accumulate
Updated
17.5.2024
First North Finland
BRETEC
Daily low / high price
2.81 / 2.86
EUR
Market cap
57.55M EUR
Turnover
17.21K EUR
Volume
6.1K
Business risk
Valuation risk
Current
Previous
Analyst
![Antti Siltanen Antti Siltanen](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://core.inderes.fi/sites/default/files/2023-08/Antti_Siltanen.jpg)
Antti Siltanen
Analyst
Latest videos
Financial calendar
Interim report
2024-08-15
Business review
2024-11-14
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Stephen Industries Inc Oy | 10.9 % | 10.9 % |
Ilmarinen Mutual Pension Insurance Company | 6.6 % | 6.6 % |
Premium
This content is for our Premium customers only.
Insider Transactions
Insider | Date | Total value |
---|---|---|
Kustaa Poutiainen | 2024-01-03 | 1,273,377EUR |
Kustaa Poutiainen | 2023-10-25 | 840,000EUR |
Premium
This content is for our Premium customers only.
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 1.5 | 2.0 | 2.9 | 3.9 | 5.5 | 8.1 | 12.2 | 18.9 |
growth-% | -14.2 % | 33.6 % | 46.9 % | 32.8 % | 40.7 % | 48.0 % | 50.0 % | 55.2 % |
EBITDA | -2.1 | -2.8 | -2.0 | -2.8 | -3.2 | -1.8 | 0.0 | 3.2 |
EBIT (adj.) | -1.9 | -2.7 | -2.3 | -3.0 | -3.5 | -2.5 | -0.7 | 2.4 |
EBIT | -1.9 | -2.7 | -2.3 | -3.0 | -3.5 | -2.5 | -0.7 | 2.4 |
Profit before taxes | -2.3 | -6.0 | -2.4 | -3.8 | -3.7 | -2.7 | -1.0 | 2.2 |
Net income | -2.3 | -6.0 | -2.4 | -3.8 | -3.7 | -2.7 | -1.0 | 2.2 |
EPS (adj.) | -0.02 | -0.43 | -0.17 | -0.20 | -0.19 | -0.14 | -0.05 | 0.11 |
growth-% | ||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -137.8 % | -141.6 % | -68.0 % | -72.6 % | -59.0 % | -22.0 % | 0.3 % | 16.9 % |
EBIT-% (adj.) | -128.4 % | -133.1 % | -77.9 % | -77.7 % | -63.2 % | -30.5 % | -5.9 % | 12.7 % |
EBIT-% | -128.4 % | -133.1 % | -77.9 % | -77.7 % | -63.2 % | -30.5 % | -5.9 % | 12.7 % |
ROE | -4,642.9 % | -211.2 % | -77.8 % | -74.7 % | -57.4 % | -85.5 % | -78.4 % | 115.4 % |
ROI | -90.4 % | -54.8 % | -46.8 % | -42.9 % | -38.1 % | -37.0 % | -12.4 % | 38.2 % |
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (EUR) | 2.70 | 1.41 | 2.40 | 2.83 | 2.83 | 2.83 | 2.83 | |
Shares | 150.4 | 14.1 | 14.1 | 19.1 | 19.5 | 19.5 | 19.5 | 19.5 |
Market cap | 38.1 | 19.8 | 45.9 | 55.3 | 55.3 | 55.3 | 55.3 | |
Enterprise value | 33.5 | 20.2 | 41.4 | 54.8 | 58.2 | 59.7 | 58.2 | |
EV/S | - | 16.7 | 6.9 | 10.6 | 10.0 | 7.2 | 4.9 | 3.1 |
EV/EBITDA | - | - | - | - | - | - | 1,472.8 | 18.2 |
EV/EBIT (adj.) | - | - | - | - | - | - | - | 24.3 |
EV/EBIT | - | - | - | - | - | - | - | 24.3 |
P/E (adj.) | - | - | - | - | - | - | - | 25.4 |
P/E | - | - | - | - | - | - | - | 25.4 |
P/B | - | 8.8 | 10.3 | 5.6 | 12.1 | 30.3 | 69.3 | 18.6 |
P/S | - | 19.0 | 6.7 | 11.8 | 10.1 | 6.8 | 4.5 | 2.9 |
Dividend yield | ||||||||
Equity ratio | 35.0 % | 50.3 % | 55.0 % | 77.2 % | 60.1 % | 31.3 % | 13.9 % | 43.5 % |
Gearing ratio | -16.2 % | -107.1 % | 17.9 % | -54.5 % | -10.8 % | 161.8 % | 556.1 % | 97.9 % |
Quarter data
Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24 | Q2/24e | Q3/24e | Q4/24e | 2024e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 1.9 | 2.0 | 3.9 | 0.7 | 1.2 | 1.7 | 1.9 | 5.5 | |
EBITDA | -1.0 | -1.8 | -2.8 | -1.1 | -0.9 | -0.7 | -0.6 | -3.2 | |
EBIT | -1.2 | -1.8 | -3.0 | -1.1 | -1.0 | -0.7 | -0.6 | -3.5 | |
Profit before taxes | -2.1 | -1.7 | -3.8 | -1.2 | -1.0 | -0.8 | -0.7 | -3.7 | |
Net income | -2.1 | -1.7 | -3.8 | -1.2 | -1.0 | -0.8 | -0.7 | -3.7 |
ShowingAll content types
Bioretec reports successful clinical outcomes from U.S. controlled launch of RemeOs™ trauma screw: fracture healing confirmed in 100% of surgical procedures
Bioretec Appoints Frank Sarcone as Vice President of Sales for the US and a member of the Management Team
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools